Goldman Sachs Group Inc Myriad Genetics Inc Transaction History
Goldman Sachs Group Inc
- $780 Billion
- Q3 2025
A detailed history of Goldman Sachs Group Inc transactions in Myriad Genetics Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,151,779 shares of MYGN stock, worth $14.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,151,779
Previous 1,283,454
67.66%
Holding current value
$14.4 Million
Previous $6.82 Million
128.28%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding MYGN
# of Institutions
236Shares Held
92.1MCall Options Held
86.1KPut Options Held
18.9K-
Black Rock Inc. New York, NY15.2MShares$102 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.88MShares$52.9 Million0.0% of portfolio
-
State Street Corp Boston, MA4.98MShares$33.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.75MShares$31.9 Million0.02% of portfolio
-
Glenview Capital Management, LLC New York, NY4.59MShares$30.8 Million0.75% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $541M
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...